Hikma Pharmaceuticals Plc (LON:HIK) has earned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is GBX 1,957.89 ($25.51).

Several research firms have issued reports on HIK. Peel Hunt reissued a “buy” rating on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, March 30th. Numis Securities Ltd reissued an “add” rating and set a GBX 2,350 ($30.61) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, March 30th. HSBC Holdings plc reissued a “reduce” rating and set a GBX 1,800 ($23.45) target price on shares of Hikma Pharmaceuticals Plc in a research note on Friday, May 5th. Stifel Nicolaus reissued a “buy” rating and set a GBX 2,550 ($33.22) target price on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, April 4th. Finally, J P Morgan Chase & Co reissued a “neutral” rating and set a GBX 2,400 ($31.27) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, April 6th.

Hikma Pharmaceuticals Plc (LON:HIK) opened at 1406.00 on Friday. The company’s market cap is GBX 3.39 billion. The stock’s 50 day moving average price is GBX 1,496.56 and its 200 day moving average price is GBX 1,818.60. Hikma Pharmaceuticals Plc has a 52-week low of GBX 1,340.00 and a 52-week high of GBX 2,703.00.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/28/hikma-pharmaceuticals-plc-lonhik-given-consensus-rating-of-hold-by-brokerages.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.